These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 6703656

  • 1. Demyelination induced by serum from patients with Guillain-Barré syndrome.
    Harrison BM, Hansen LA, Pollard JD, McLeod JG.
    Ann Neurol; 1984 Feb; 15(2):163-70. PubMed ID: 6703656
    [Abstract] [Full Text] [Related]

  • 2. [Electrophysiological and morphological effects of the injection of Guillain-Barré sera in the sciatic nerve of the rat (author's transl)].
    Sumner A, Said G, Idy I, Metral S.
    Rev Neurol (Paris); 1982 Feb; 138(1):17-24. PubMed ID: 7100734
    [Abstract] [Full Text] [Related]

  • 3. Demyelination in vivo by Guillain-Barré syndrome and other human serum.
    Brown MJ, Rosen JL, Lisak RP.
    Muscle Nerve; 1987 Feb; 10(3):263-71. PubMed ID: 3561445
    [Abstract] [Full Text] [Related]

  • 4. In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome.
    Saida T, Saida K, Lisak RP, Brown MJ, Silberberg DH, Asbury AK.
    Ann Neurol; 1982 Jan; 11(1):69-75. PubMed ID: 7059130
    [Abstract] [Full Text] [Related]

  • 5. In vivo effects of sera from Guillain-Barré subgroups: an electrophysiological and histological study on rat nerves.
    Oomes PG, van der Meché FG, Markus-Silvis L, Meulstee J, Kleyweg RP.
    Muscle Nerve; 1991 Oct; 14(10):1013-20. PubMed ID: 1658645
    [Abstract] [Full Text] [Related]

  • 6. [4 cases of Guillain-Barré syndrome with axonal lesions].
    Vallat JM, Hugon J, Tabaraud F, Leboutet MJ, Chazot F, Dumas M.
    Rev Neurol (Paris); 1990 Oct; 146(6-7):420-4. PubMed ID: 2399405
    [Abstract] [Full Text] [Related]

  • 7. In vitro demyelination by serum antibody from patients with Guillain-Barré syndrome requires terminal complement complexes.
    Sawant-Mane S, Clark MB, Koski CL.
    Ann Neurol; 1991 Apr; 29(4):397-404. PubMed ID: 1718212
    [Abstract] [Full Text] [Related]

  • 8. Serum-induced demyelination: an electrophysiological and histological study.
    Pollard JD, Harrison B, Gatenby P.
    Clin Exp Neurol; 1981 Apr; 18():70-80. PubMed ID: 6926394
    [Abstract] [Full Text] [Related]

  • 9. [Serum demyelinating activity and Guillain-Barre syndrome: favorable effect of plasma exchange].
    Metral S, Raphael JC, Hort-Legrand CI, Elkharrat D.
    Rev Neurol (Paris); 1989 Apr; 145(4):312-9. PubMed ID: 2660223
    [Abstract] [Full Text] [Related]

  • 10. Conduction block--the diagnostic value in the early stage of Guillain-Barre syndrome.
    Atanasova D, Ishpekova B, Muradyan N, Novachkova S, Daskalov M.
    Electromyogr Clin Neurophysiol; 2004 Sep; 44(6):361-4. PubMed ID: 15473348
    [Abstract] [Full Text] [Related]

  • 11. Antiserum-mediated demyelination: relationship between remyelination and functional recovery.
    Saida K, Sumner AJ, Saida T, Brown MJ, Silberberg DH.
    Ann Neurol; 1980 Jul; 8(1):12-24. PubMed ID: 7406444
    [Abstract] [Full Text] [Related]

  • 12. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
    Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV.
    Ann Neurol; 1998 Nov; 44(5):780-8. PubMed ID: 9818934
    [Abstract] [Full Text] [Related]

  • 13. Mitomycin C induces a delayed and prolonged demyelination and conduction block due to Schwann cell destruction.
    Westland K, Pollard JD, Sumner AJ.
    Clin Exp Neurol; 1990 Nov; 27():65-78. PubMed ID: 2129960
    [Abstract] [Full Text] [Related]

  • 14. Electrophysiological studies of Guillain-Barré syndrome with different susceptibilities to develop EAN serum on 2 strains of rats.
    Low PA, Schmelzer J, Dyck PJ, Kelly JJ.
    Electroencephalogr Clin Neurophysiol Suppl; 1982 Nov; 36():81-90. PubMed ID: 6984386
    [Abstract] [Full Text] [Related]

  • 15. Simulating focal demyelinating neuropathies: membrane property abnormalities.
    Stephanova DI, Alexandrov AS, Kossev A, Christova L.
    Biol Cybern; 2007 Feb; 96(2):195-208. PubMed ID: 17072638
    [Abstract] [Full Text] [Related]

  • 16. Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies.
    Bergin PS, Miller DH, Hirsch NP, Murray NM.
    Ann Neurol; 1993 Sep; 34(3):406-9. PubMed ID: 8363359
    [Abstract] [Full Text] [Related]

  • 17. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis.
    Hartung HP, Reiners K, Schmidt B, Stoll G, Toyka KV.
    Ann Neurol; 1991 Jul; 30(1):48-53. PubMed ID: 1929228
    [Abstract] [Full Text] [Related]

  • 18. [The Guillain-Barré syndrome].
    Piradov MA, Lozhnikova SM, Sakharova AV, Liudkovskaia IG, Nikitin SS.
    Arkh Patol; 1994 Jul; 56(5):73-9. PubMed ID: 7535047
    [Abstract] [Full Text] [Related]

  • 19. [Effector mechanisms of PNS demyelination in Gal-C induced-EAN].
    Saida K.
    Rinsho Shinkeigaku; 1990 Dec; 30(12):1361-3. PubMed ID: 2129197
    [Abstract] [Full Text] [Related]

  • 20. Acute conduction block associated with experimental antiserum-mediated demyelination of peripheral nerve.
    Sumner AJ, Saida K, Saida T, Silberberg DH, Asbury AK.
    Ann Neurol; 1982 May; 11(5):469-77. PubMed ID: 6285800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.